(Total Views: 538)
Posted On: 12/28/2020 2:07:47 PM
Post# of 148954
“NASH as per my understanding of LL's MoA is one disease where very strong efficacy is a very likely outcome.”
Yes, the results of the preclinical studies for NASH were very good. Honestly, the NASH trial is a non-factor until later 2021 or early 2022, unless enrollment is fast. CYDY and other biotechs typically enroll trials slowly due to cost and reach.
Yes, the results of the preclinical studies for NASH were very good. Honestly, the NASH trial is a non-factor until later 2021 or early 2022, unless enrollment is fast. CYDY and other biotechs typically enroll trials slowly due to cost and reach.
(2)
(0)Scroll down for more posts ▼
